Mereo Biopharma Group Plc ADR (MREO) Unusual Options Activity Today

Checking MREO unusual options activity helps you spot when traders are making outsized bets on Mereo Biopharma Group Plc ADR before the broader market catches on. Mereo Biopharma Group Plc ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor MREO unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching MREO unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking MREO unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and MREO unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism.

In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Catalysts rarely arrive without a footprint, and MREO unusual options activity is often where that footprint shows up first. Our scanner tracks Mereo Biopharma Group Plc ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at MREO unusual options volume on the call side or chasing put sweeps, Mereo Biopharma Group Plc ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.